Le Lézard
Classified in: Health, Business
Subject: CCA

InMode to Present at Upcoming Investor Conferences and Events


YOKNEAM, Israel, April 3, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in April and May:

23rd Annual Needham Virtual Healthcare Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Chairman, Yair Malca, Chief Financial Officer and Spero Theodorou, Chief Medical Officer
Format: Virtual fireside chat moderated by Michael Matson, CFA and Senior Equity Research Analyst and one-on-one meetings
When: Tuesday, April 9 at 8:00 am ET
A live webcast of the presentation can be accessed here.

BNPP Exane 2nd Annual Aesthetics Day
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer, and Dr. Spero Theodorou, Chief Medical Officer
Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings
When: Tuesday, May 21 at 1:30 pm ET
A replay of webcast of the presentation can be accessed here.

Barclays West Coast Bus Trip
Presenters: Yair Malca, Chief Financial Officer
Format: In-person investor bus tour at InMode's North American headquarters
When: Tuesday, May 21
Location: Irvine, CA

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Investor Relations Contact:

Miri Segal-Scharia
MS-IR LLC
[email protected]
917-607-8654 

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

SOURCE InMode LTD


These press releases may also interest you

at 18:00
Lifeist Announces Common Share Consolidation
Lifeist Wellness Inc. ("Lifeist" or the "Company") , a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that its Board of Directors has approved...

at 17:44
13 Caps and Counting, the Maplewood at Strawberry Hill Community Honors its Own
This National Volunteer Month, while many organizations honored local volunteers who generously gave of their time and talents all year long, one community also saluted its own. Meet Maplewood at Strawberry Hill?the vibrant senior living community...

at 17:31
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight
DelveInsight's Medical Dynamometers Market Insights report provides the current and forecast market analysis, individual leading medical dynamometers companies' market shares, challenges, medical dynamometers market drivers, barriers, trends, and...

at 17:31
CHEMISTREE ANNOUNCES RESULTS FROM ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), announces the results of matters voted on at the Company's annual general and special meeting of shareholders (the "Meeting") held earlier today....

at 17:20
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution...

at 17:15
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024. One individual was...

More news about Health...


News published on and distributed by: